Back to Ovarian Cancer
NCT01422265
NCT01422265
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma (confirmed by a tissue sample/biopsy), and it came back more than 6 months after you finished platinum-based chemotherapy
- This is the first time your cancer has come back after your original treatment
- You finished your second round of cancer treatment (chemotherapy) at least 2 weeks ago but no more than 3 months ago
- You are currently being monitored or receiving a drug called bevacizumab as a maintenance therapy after your second round of treatment
- You have a valid email address and regular access to the internet
- You are willing and able to sign a consent form agreeing to take part in the study
- You can speak and read English fluently
Who may not be able to join:
- You are currently taking part in another clinical trial for ovarian cancer treatment where neither you nor your doctor knows which treatment you are receiving (note: being in a trial that only involves supportive care medicines or growth factors is acceptable)
- You have been diagnosed with a second, separate type of cancer in a different part of your body
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Genentech, Inc.
Registry
clinicaltrials_gov
Start date
1 June 2011
Est. completion
1 April 2015
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Change in MD Anderson Symptom Inventory-Ovarian Cancer (MDASI-OC) sub-set symptom severity score before and after disease progression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.